Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director · 10% owner | May 29, 2024 | May 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tyra Biosciences, Inc.
Report date May 29, 2024 · Filed May 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.94 · Expires 2034-05-28 | Direct | 18,600 |
Reported balance
After 2024-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-29 · Grant · Acquired 18,600 · Balance 18,600 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2024, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. F2: These securities are owned directly by the Reporting Person, who may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC, (iv) Joseph C. Lewis, (v) Aaron Davis and (vi) the Reporting Person (collectively, the "Boxer Group"). Each member of the Boxer Group other than the Reporting Person disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2024, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F2: These securities are owned directly by the Reporting Person, who may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC, (iv) Joseph C. Lewis, (v) Aaron Davis and (vi) the Reporting Person (collectively, the "Boxer Group"). Each member of the Boxer Group other than the Reporting Person disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2024 Filed May 31, 2024 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 18,600 | $0.00 Strike: $15.94 | $0.00 |
DisclosureSEC source: 0000950170-24-067363 · ownership.xml · derivative · entry 1 Subramony Siddarth · CIK 0001880624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2034-05-28 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2024, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. F2 · ownership.direct: These securities are owned directly by the Reporting Person, who may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC, (iv) Joseph C. Lewis, (v) Aaron Davis and (vi) the Reporting Person (collectively, the "Boxer Group"). Each member of the Boxer Group other than the Reporting Person disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0001209191-23-033779 · doc4.xml · derivative · entry 1 Subramony Siddarth · CIK 0001880624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2033-05-30 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. F2 · ownership.direct: These securities are owned directly by the Reporting Person, who may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC, (iv) Joseph C. Lewis, and (v) the Reporting Person (collectively, the "Boxer Group"). Each member of the Boxer Group other than the Reporting Person disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001209191-22-036994 · doc4.xml · derivative · entry 1 Subramony Siddarth · CIK 0001880624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2032-06-12 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 13, 2022, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. F2 · ownership.direct: These securities are owned directly by the Reporting Person, who may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC, (iv) Joseph C. Lewis, and (v) the Reporting Person (collectively, the "Boxer Group"). Each member of the Boxer Group other than the Reporting Person disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.